Management of Cerebral Tuberculomas

Standard Treatment Regimen

The American Thoracic Society recommends a 12-month regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol for the first 2 months, followed by rifampicin and isoniazid for 10 additional months for cerebral tuberculomas 1, 2, 3
Administer four drugs daily: rifampicin (10 mg/kg, up to 600 mg if >50 kg or 450 mg if <50 kg), isoniazid (5 mg/kg, up to 300 mg), pyrazinamide (35 mg/kg, up to 2.0 g if >50 kg or 1.5 g if <50 kg), and ethambutol (15 mg/kg) 1, 2, 3
The fourth drug (ethambutol, streptomycin, or ethionamide) is essential during the initial phase for cerebral tuberculomas 1, 2

Isoniazid, pyrazinamide, and prothionamide/ethionamide penetrate well into cerebrospinal fluid 1, 3
Rifampicin penetrates less effectively but remains critical to the regimen 1, 3

Extend treatment to 18 months if pyrazinamide is omitted or cannot be tolerated 1, 2, 3
Use rifampicin, isoniazid, and ethambutol for the initial 2 months, then continue rifampicin and isoniazid for 16 additional months if pyrazinamide cannot be used 1

Corticosteroids are recommended for more severe disease (stages II and III): use prednisolone 60 mg daily initially, with gradual tapering over several weeks 1, 2, 3, 4

Add a later-generation fluoroquinolone (moxifloxacin or levofloxacin) to a regimen of rifampicin, ethambutol, and pyrazinamide for 6 months for isoniazid-resistant tuberculomas 2, 4
Treat rifampicin-resistant tuberculomas with 18 months total: 2 months of isoniazid, pyrazinamide, and ethambutol, followed by 16 additional months of isoniazid plus ethambutol 5, 6

Monitor response clinically and with neuroimaging throughout treatment 2, 3
Visual acuity must be monitored throughout due to ethambutol's potential ocular toxicity 4

Use the same 12-month regimen with weight-adjusted dosing for pediatric patients: isoniazid 10-15 mg/kg (up to 300 mg daily), rifampicin 10 mg/kg, pyrazinamide 35 mg/kg, and ethambutol 15 mg/kg 1, 2, 3

Do not use the standard 6-month regimen for tuberculomas—this is inadequate and applies only to respiratory and most non-respiratory tuberculosis 1, 7
Do not omit the fourth drug in the initial phase for CNS tuberculosis, even in low-resistance settings 1
Do not assume rifampicin resistance is isolated—treat as MDR-TB until proven otherwise 5, 6